72 A Novel Biosignature for Early- Stage Invasive Breast Cancer to Predict Radiotherapy Benefit and Assess Recurrence Risk for Patients Treated With Breast- Conserving Surgery

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement41st Annual Miami Breast Cancer Conference® - Abstracts
Volume 38
Issue 4
Pages: 81-82

A Novel Biosignature for Early- Stage Invasive Breast Cancer to Predict Radiotherapy Benefit and Assess Recurrence Risk for Patients Treated With Breast- Conserving Surgery

A Novel Biosignature for Early- Stage Invasive Breast Cancer to Predict Radiotherapy Benefit and Assess Recurrence Risk for Patients Treated With Breast- Conserving Surgery

Background

Adjuvant radiation therapy (RT) represents a standard of care for most patients with early-stage, hormone receptor–positive (HR+) invasive breast cancer (IBC) following breast-conserving surgery (BCS). Ongoing studies are exploring the integration of clinical and biological factors to better assess patient-specific recurrence risk profiles to de-escalate treatment while including the use of RT safely and appropriately. Acknowledging the intricate tumor biology influenced by the tumor microenvironment, the present study evaluates multiple cellular processes corresponding to tumor intrinsic and immunophenotypes as predictive markers for RT response as a part of a biosignature for HR+ IBC.

Methods

A multi-institutional cohort (1987-2022) of women diagnosed with IBC was examined to identify a subset of 708 HR+, T1/T2N0M0 patients who underwent BCS with a median follow-up of 126 months. Treatment included BCS with or without RT based on physician preference. A biosignature that calculates an individualized risk profile was developed and cross-validated. The association between the biosignature and the 10-year recurrence rate (local and distant) was assessed. RT benefit was assessed by risk group and as a function of the biosignature score using survival analyses and multivariable Cox proportional hazards adjusted for treatment, clinicopathologic (CP) risk factors age, grade, and tumor size.

Results

The patient cohort had a median age of 63 years, with 661 of 708 patients being T1 and the remaining patients being T2. Twenty percent of the patients had grade 3 disease, and 80% were grade 1/2. A total of 253 patients received endocrine therapy (ET), and 584 received RT (205 of patients receiving ET received RT). The biosignature score identified a low-risk group with 10-year recurrence rate of 1% negative or positive +RT (HR, ≈ 1; P = 1; n = 146), an elevated risk group with 20% negative RT and 13% +positive RT (HR, 0.5; P = .02; n = 462) and a residual risk group with 30% negative or positive plus RT (HR, ≈ 1; P = .95; n = 96). In a multivariable analysis adjusted for treatment and CP factors, the interaction (biosignature score: RT) was significant (P < .001), and ET tended to decrease therecurrence rate (HR, 0.7; P = .09).

Conclusions

The biosignature identified clinically meaningful risk groups with differential RT benefit associated with 10-year recurrence rate and a residual risk group with an elevated 10-year recurrence rate remaining after BCS plus RT. With further validation, the biosignature may be useful to aid in the assessment of RT benefit in early-stage IBC.

Articles in this issue

42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery
42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery
43 Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction
43 Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction
44 Variant of Uncertain Significance (VUS) Genetic Testing Results and Mastectomy Choice in Lumpectomy-Eligible Patients
44 Variant of Uncertain Significance (VUS) Genetic Testing Results and Mastectomy Choice in Lumpectomy-Eligible Patients
45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?
45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?
46 Comparative Analysis of Breast Conserving Therapy vs Mastectomy in Multifocal and Multicentric Breast Cancer: A Review of the Literature
46 Comparative Analysis of Breast Conserving Therapy vs Mastectomy in Multifocal and Multicentric Breast Cancer: A Review of the Literature
47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?
47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?
48 The Era ‘or Error’ of Second Localization Procedures
48 The Era ‘or Error’ of Second Localization Procedures
49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study
49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study
51 Ductal Carcinoma In Situ With Microinvasion on Biopsy—What Are the Predictors of Upstaging?
51 Ductal Carcinoma In Situ With Microinvasion on Biopsy—What Are the Predictors of Upstaging?
52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy
52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left  Breast Cancer
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left Breast Cancer
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
57 Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice
57 Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
Related Content